Clinical Approach to a 57-Year-Old Female with Fever, Thrombocytopenia, and Pregabalin Use
Immediately investigate the thrombocytopenia and fever as potentially serious complications, while recognizing that pregabalin is appropriately treating her restless leg syndrome per current guidelines.
Immediate Priority: Assess Thrombocytopenia Severity and Etiology
The combination of fever and unexplained thrombocytopenia requires urgent evaluation to rule out life-threatening conditions, particularly given her current vital stability (SpO₂ 98%, pulse 84 bpm, BP 110/70 mmHg, temperature 37.5°C - which is borderline fever).
Critical First Steps:
Obtain complete blood count with peripheral smear immediately to assess:
- Platelet count severity (risk stratification: <10,000-20,000/μL requires prophylactic transfusion consideration; <50,000/μL before procedures) 1
- Presence of schistocytes (suggests thrombotic microangiopathy requiring emergency intervention) 1
- Other cell lines (pancytopenia suggests bone marrow pathology)
Rule out emergent causes requiring immediate intervention 1:
- Thrombotic microangiopathy (TMA) - requires rapid therapeutic intervention
- Disseminated intravascular coagulation (DIC)
- Heparin-induced thrombocytopenia (HIT) - though no heparin mentioned
Assess bleeding risk:
- Check for petechiae, purpura, mucosal bleeding
- Avoid intramuscular injections until platelet count known
Evaluate Pregabalin as Potential Cause
Pregabalin can cause thrombocytopenia and fever as documented adverse effects, though this is uncommon 2, 3.
Key Considerations:
- The FDA label explicitly warns that pregabalin may cause "bleeding problems or low blood platelet count" 2
- A case report documented thrombocytopenia (platelets dropping from 131 to 73 × 10⁹/L) with fever (39.2°C) and neuropsychiatric symptoms following pregabalin 75 mg 3
- However, her current dose (150 mg) is appropriate for RLS per 2025 AASM guidelines 4
Critical Decision Point:
Do NOT discontinue pregabalin immediately unless:
- Platelet count is critically low (<20,000/μL)
- Evidence of drug-induced immune thrombocytopenia
- Severe bleeding manifestations
Rationale: The 2025 AASM guidelines give pregabalin a strong recommendation for RLS treatment 4. Abrupt discontinuation causes withdrawal symptoms (headache, nausea, anxiety, insomnia) 2.
Investigate Fever Source
With temperature 37.5°C (borderline), assess for:
Infection workup:
- Blood cultures (before antibiotics if sepsis suspected)
- Urinalysis and culture
- Chest X-ray if respiratory symptoms
- Consider procalcitonin or CRP if bacterial infection probability is low-to-intermediate 5
Underlying hematologic malignancy: Unexplained thrombocytopenia warrants consideration
Address Bereavement-Related Insomnia
Avoid medications that worsen RLS 4:
- Do NOT use: Antihistamines (diphenhydramine), serotonergic antidepressants, or dopamine antagonists - these exacerbate RLS 4, 6
- Consider: Non-pharmacologic sleep hygiene measures first 7
- If medication needed: Low-dose trazodone or mirtazapine (less RLS exacerbation than SSRIs)
Important caveat: The 2025 AASM guidelines specifically recommend against clonazepam for RLS 4, so benzodiazepines should be avoided.
Specific Diagnostic Algorithm
Step 1: Laboratory Evaluation (Immediate)
- CBC with differential and peripheral smear
- Comprehensive metabolic panel (assess renal function - pregabalin is renally cleared)
- Coagulation studies (PT/INR, aPTT, fibrinogen, D-dimer)
- Blood cultures × 2 if infection suspected
- Iron studies (ferritin, transferrin saturation) - critical for RLS management 4
Step 2: Risk Stratification Based on Platelet Count
- <10,000/μL: Consider prophylactic platelet transfusion (unless ITP or TTP) 1
- 10,000-50,000/μL: Close monitoring, avoid invasive procedures
- >50,000/μL: Generally safe, but investigate cause
Step 3: Determine Thrombocytopenia Etiology
- Drug-induced (pregabalin): Temporal relationship, improvement with discontinuation
- Immune-mediated (ITP): Isolated thrombocytopenia, no splenomegaly 8
- Infection-related: Fever, positive cultures
- Pregnancy-related: Rule out (though age 57 makes this unlikely)
- Hematologic malignancy: Requires bone marrow biopsy if other causes excluded
Step 4: Pregabalin Management Decision
If platelets >50,000/μL and no bleeding:
- Continue pregabalin 150 mg
- Monitor CBC every 2-3 days initially
- Optimize iron status (ferritin ≤75 ng/mL or transferrin saturation <20% warrants supplementation) 4
If platelets 20,000-50,000/μL:
- Consider dose reduction to 75 mg
- Add alternative RLS treatment if symptoms worsen
- Daily CBC monitoring
If platelets <20,000/μL or active bleeding:
- Discontinue pregabalin (taper over 1 week if possible to minimize withdrawal) 2
- Switch to alternative RLS treatment: gabapentin or gabapentin enacarbil (also strong AASM recommendation) 4
- Consider IV iron if ferritin ≤100 ng/mL 4
Common Pitfalls to Avoid
- Do not assume thrombocytopenia is benign - always rule out TMA and DIC first 1
- Do not prescribe antihistamines for insomnia - they worsen RLS 4, 6
- Do not abruptly stop pregabalin - causes withdrawal and rebound RLS 2
- Do not overlook iron deficiency - check iron studies in all RLS patients 4
- Do not use dopamine agonists as first-line - 2025 guidelines now recommend against standard use due to augmentation risk 4
Monitoring Plan
- Daily: Clinical assessment for bleeding, fever curve
- Every 2-3 days: CBC until platelet count stable
- Weekly: Renal function (pregabalin is renally cleared; dose adjust if CrCl <60 mL/min)
- 2-4 weeks: Iron studies, RLS symptom severity assessment
The key is systematic evaluation of thrombocytopenia while maintaining appropriate RLS treatment, avoiding medications that worsen RLS, and addressing the acute stressor (bereavement) with non-pharmacologic approaches first.